Pertuzumab, a monoclonal antibody, targets the extracellular dimerization domain of the human epidermal growth factor 2 (HER2) protein but at a different subdomain to trastuzumab. It inhibits ligand-initated intracellular signalling, resulting in cell growth arrest and apoptosis.1
Pertuzumab was investigated in the pivotal randomised, double-blind, placebo-controlled phase III trial CLEOPATRA in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.1,2
Patients given pertuzumab, in combination with trastuzumab and docetaxel, had a median progression-free survival of 18.5 months compared with 12.4 months for those in the placebo arm (HR=0.62, 95% CI 0.52–0.75; p<0.0001).2
The most common adverse reactions reported were diarrhoea, alopecia and neutropenia.1,2
- Perjeta Summary of Product Characteristics, March 2013
- Baselga J et al. N Engl J Med 2012; 366: 109-19.